CJC-1295 | Ipamorelin

CJC-1295 + Ipamorelin is a combination of two peptides designed to naturally boost the body's own growth hormone (GH) production and its related effects, particularly IGF-1. CJC-1295 is a long-acting compound that binds to albumin in the blood, allowing it to stay in the system for about 6-8 days after a single injection, leading to sustained increases in GH and IGF-1.

Ipamorelin, on the other hand, works selectively on the pituitary gland to trigger quick, natural-like bursts of GH, without significantly affecting other hormones like cortisol or prolactin. When used together, these peptides work synergistically: CJC-1295 provides a steady elevation of GH and IGF-1, while Ipamorelin adds natural, pulsatile GH release, leading to a more effective and physiological overall increase in growth hormone activity. Human studies have shown this combination effectively activates the GH/IGF-1 system.

Enhanced Growth Hormone Levels: Leads to significant and sustained increases in GH and IGF-1, with added natural growth hormone pulses. (Human Study)
Improved Body Composition: May help increase lean muscle mass and reduce body fat by boosting protein building and fat breakdown. (Human Study)
Faster Recovery: Supports the body's ability to heal and repair tissues, including collagen, after exercise or injury. (Human Study)
Better Sleep: May improve sleep quality, particularly deeper sleep cycles, and enhance overall well-being. (Human Study)
Reduced Side Effects: Ipamorelin specifically targets GH release with minimal impact on cortisol or prolactin, leading to a better safety profile. (Lab Study)
Convenient Dosing: CJC-1295's long-lasting effect allows for infrequent dosing, often once or twice a week. (Human Study)
Trackable Results: Changes in certain blood markers, including IGF-1, can be used to monitor the effectiveness of CJC-1295. (Human Study)

Teichman, S.L., et al. (2006). Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805.
Ionescu, M., et al. (2006). Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I in healthy adults. PubMed 16352683.
Sackmann-Sala, L., et al. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog: serum proteomic biomarkers before and after dosing. Endocrine Abstracts, 19, P83.
Yin, Y., et al. (2014). The Growth Hormone Secretagogue Receptor (GHSR1a): signaling and functional relevance. International Journal of Molecular Sciences, 15(3), 4837–4855.
Liu, H., et al. (2021). Structural basis of human ghrelin receptor signaling by ghrelin and GHRP. Nature Communications, 12, 5064.

$92.00

Per Unit

In stock